Table 2.
Tests capable of satisfactorily excluding/diagnosing advanced fibrosis (negative and positive likelihood ratios <0.25 and >5.0, respectively)
| Excluding advanced fibrosis
| ||||
|---|---|---|---|---|
| Biomarkers | Cut-off | Sensitivity | Specificity | Negative likelihood |
| APRI39 | <1.5 | 87% | 50% | 0.26 |
| Hepascore53 | <0.5 | 88% | 74% | 0.16 |
| MP354 | <0.40 | 92% | 58% | 0.14 |
|
| ||||
| Elastography | ||||
|
| ||||
| Fibroscan55 | <8.0 | 89% | 89% | 0.12 |
| 2D-SWE48 | <8.7 | 97% | 95% | 0.03 |
| pSWE (ARFI)49 | <1.54 | 97% | 100% | 0.03 |
|
| ||||
| Diagnosing advanced fibrosis | ||||
|
| ||||
| Biomarkers | Cut-off | Sensitivity | Specificity | Positive likelihood |
|
| ||||
| APRI39 | >2.0 | 36% | 93% | 5.2 |
| MP354 | >0.4 | 58% | 92% | 7.25 |
| Pohl Index85 | Positive | 41% | 89% | 5.36 |
| CDS86 | >8.0 | 46% | 91% | 5.11 |
|
| ||||
| Elastography | ||||
|
| ||||
| Fibroscan55 | >9.5 | 73% | 91% | 8.1 |
| 2D-SWE48 | >8.7 | 97% | 95% | 19.7 |
| pSWE (ARFI)56 | >1.61 | 79% | 95% | 15.3 |
Note: Information based on individual studies compiled; no head-to-head comparisons were made. Tests and components: APRI: AST, platelets; Hepascore®: Gender, GGT, Total Bilirubin, Hyaluronate, Alfa2-macroglobulin; MP3: PIIMP and MMP-1; Pohl Index: AST/ALT, Platelets; CDS: AST/ALT, Platelets.
Abbreviations: 2D-SWE, two-dimensional shear-wave elastography; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; GGT, gamma glutamyl transferase; MMP-1, metalloproteinase 1; PIIMP, N-terminal propeptide from type II collagen; pSWE (ARFI), point shear-wave elastography (acoustic radiation force impulse).